NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis $2.20 -0.04 (-1.79%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.09▼$2.2150-Day Range$2.11▼$3.0452-Week Range$2.09▼$4.75Volume5,349 shsAverage Volume22,008 shsMarket Capitalization$115.45 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Inventiva alerts: Email Address Inventiva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside718.2% Upside$18.00 Price TargetShort InterestBearish0.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.40) to ($2.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.97 out of 5 starsMedical Sector758th out of 910 stocksPharmaceutical Preparations Industry354th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingInventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInventiva has received no research coverage in the past 90 days.Read more about Inventiva's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.25% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Inventiva has recently decreased by 2.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVA. Previous Next 0.6 News and Social Media Coverage News SentimentInventiva has a news sentiment score of -0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.06% of the stock of Inventiva is held by institutions.Read more about Inventiva's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inventiva are expected to decrease in the coming year, from ($2.40) to ($2.51) per share.Read more about Inventiva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Inventiva Stock (NASDAQ:IVA)Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More IVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVA Stock News HeadlinesAugust 15, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)August 1, 2024 | finanznachrichten.deINVENTIVA: Inventiva Reports Preliminary 2024 First-Half Financial InformationSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.July 31, 2024 | globenewswire.comInventiva Reports Preliminary 2024 First-Half Financial Information¹July 25, 2024 | finanznachrichten.deINVENTIVA: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | globenewswire.comInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 19, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces a €20.1 million issuance of royalty certificatesJuly 19, 2024 | globenewswire.comHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.July 18, 2024 | globenewswire.comInventiva announces a €20.1 million issuance of royalty certificatesJuly 5, 2024 | globenewswire.comInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial positionJune 21, 2024 | globenewswire.comResults of the votes of the Combined Shareholders' General Meeting of June 20, 2024May 30, 2024 | globenewswire.comCombined General Meeting of June 20, 2024 - Availability of the preparatory documentsMay 28, 2024 | seekingalpha.comAltimmune: A Potential Minor Player In The Massive GLP-1 SpaceMay 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces two scientific presentations at the EASL International Liver Congress 2024May 22, 2024 | globenewswire.comInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024May 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports 2024 First Quarter Financial Information and provides a corporate updateMay 21, 2024 | globenewswire.comInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateSee More Headlines Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Next Earnings (Confirmed)9/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVA CUSIPN/A CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees100Year Founded2011Price Target and Rating Average Stock Price Target$18.00 High Stock Price Target$25.00 Low Stock Price Target$11.00 Potential Upside/Downside+718.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.95 Sales & Book Value Annual Sales$17.48 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-3.28Miscellaneous Outstanding Shares52,477,000Free Float35,684,000Market Cap$115.45 million OptionableNot Optionable Beta0.97 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Frederic Cren (Age 58)Co-Founder, CEO & Chairman Comp: $519.9kDr. Pierre Broqua Ph.D. (Age 62)Co-Founder, Chief Scientific Officer, Deputy CEO & Director Comp: $449.01kMr. Jean Volatier (Age 59)Deputy GM & CFO Ms. Alice Roudot-Ketelers Pharm.D. (Age 53)Chief Operating Officer Mr. Eric Duranson L.L.M. (Age 50)General Counsel Ms. Nathalie Harroy (Age 57)Head of Human Resources Dr. Michael Cooreman (Age 66)Chief Medical Officer Ms. Pascaline Clerc Ph.D. (Age 44)Executive Vice President of Strategy & Corporate Affairs More ExecutivesKey CompetitorsErascaNASDAQ:ERASTerns PharmaceuticalsNASDAQ:TERNAnavex Life SciencesNASDAQ:AVXLAlectorNASDAQ:ALECAltimmuneNASDAQ:ALTView All Competitors IVA Stock Analysis - Frequently Asked Questions How have IVA shares performed this year? Inventiva's stock was trading at $4.52 at the start of the year. Since then, IVA shares have decreased by 51.3% and is now trading at $2.20. View the best growth stocks for 2024 here. When did Inventiva IPO? Inventiva (IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.